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Background: The purpose of the analysis was to develop a health economic model to estimate the costs and
health benefits of alternative National Health Service (NHS) service configurations for people with longer-term
depression.
Method: Modelling methods were used to develop a conceptual and health economic model of the current
configuration of services in Sheffield, England for people with longer-term depression. Data and assumptions were
synthesised to estimate cost per Quality Adjusted Life Years (QALYs).
Results: Three service changes were developed and resulted in increased QALYs at increased cost. Versus current
care, the incremental cost-effectiveness ratio (ICER) for a self-referral service was £11,378 per QALY. The ICER was
£2,227 per QALY for the dropout reduction service and £223 per QALY for an increase in non-therapy services.
These results were robust when compared to current cost-effectiveness thresholds and accounting for uncertainty.
Conclusions: Cost-effective service improvements for longer-term depression have been identified. Also identified
were limitations of the current evidence for the long term impact of services.
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The majority of people with depression will experience a
full recovery, however for some the outlook is uncertain.
This includes people whose depression is a chronic con-
dition (sometimes called ‘treatment resistant’ depression)
and those who have recurrent episodes of major depres-
sion (also termed ‘relapsing’ depression). Attention was
drawn to the importance of this group as early as 1977
[1], and there is a growing body of research specifically
focusing on their needs [2]. The awareness that depres-
sion for many people is a lifelong condition has yet to
make a significant impact on the way mental health ser-
vices are designed and delivered. Yet efficient services
and effective treatments would have significant implica-
tions, in terms of health outcomes and service utilisation* Correspondence: j.tosh@sheffield.ac.uk
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reproduction in any medium, provided the orover a persons’ remaining lifetime [3]. For example, in
the UK an Office of National Statistics study in 2000 es-
timated the total direct costs of depression for the NHS
as £370 m, along with significant indirect costs for the
economy (£8bn total morbidity costs, £562 m total mor-
tality costs) [4]. It is clear from this study, and other
similar cost-of-illness studies [5,6] that depression im-
poses a significant burden on individuals, carers, the
health service and the wider economy. Therefore it is of
fundamental importance to ensure that health care re-
sources are efficiently used to maximise health benefits
for people with longer-term depression.
The ‘Improving Quality and Effectiveness of Services
Therapies and Self-management for longer-term depres-
sion’ (IQuESTS) study is a collaborative research project
undertaken by mental health service providers, commis-
sioners and health service researchers. It is committed
to translating the results of research to routine NHS
care, by improving self-management, and demonstratingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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logical therapies (PT) and services.
There are many potentially cost-effective interventions
that may improve the quality and outcomes of services
for people with longer-term depression. A number of
these are included under the generic term ‘collaborative
care’, a systematic approach which supplements primary
medical care with mental health interventions from a
range of practitioners [7]. Examples with economic evalua-
tions include behavioural activation [8], problem-solving
[9], nurse-led self-help [10], family psychoeducation [11],
and the UK collaborative and stepped care initiative ‘Im-
proving Access to Psychological Therapies (IAPT) [12].
These evaluations of single interventions or programmes
do not meet the requirements of the IQuESTS project for
a framework to examine, within a local community, the
multiplicity of people’s care pathways through the whole
system and to estimate the likely impacts on costs and
outcomes of changes to that system.
This analysis is the first of three work packages of the
IQuESTS project, where the cost-effectiveness of poten-
tial service improvements is estimated. This analysis,
together with a qualitative study of service user self-
management, has informed the final work package
where evidence-based innovations are being tested in
routine services.
When considering ways to improve clinical effective-
ness and service quality across the whole care pathway
in longer-term depression, it is important to be able to
estimate which innovations are likely to be cost-effective,
as has been demonstrated for specific service configura-
tions, such as collaborative care [7]. A cost-effectiveness
analysis is a method of economic evaluation that con-
siders both the additional health benefits and additional
costs of a new intervention or service development to de-
termine whether they represent value for money. Health
benefits can be measured using Quality Adjusted Life
Years (QALYs), a measure that combines length of life
with health-related quality of life (HRQL) [13]. HRQL
values are scaled, where 1 represents full health and 0 is
equivalent to death. An 18 month depressive episode
with HRQL of 0.4 would equal 0.6 QALYs. Lifetime
QALYs are calculated by aggregating the QALYs for each
health state. To compare alternative possibilities, incre-
mental costs and incremental QALYs between compara-
tors are calculated. The ratio of these is called the
incremental cost-effectiveness ratio (ICER).
The National Institute for Health and Clinical Excel-
lence (NICE) is an independent organisation in the UK
that provides guidance on the use of treatments in the
NHS. Although drugs and treatments approved by NICE
technology appraisals are mandatory for local services to
fund and implement, other NICE guidance (such as pub-
lic health guidance and clinical guidelines) are not. Localservices must take NICE guidance into account but it
does not replace the knowledge and skills of individual
health professionals who treat patients; it is still up to
them to make decisions about a particular patient in
consultation with the patient and/or their guardian or
carer when appropriate. Resource allocation decisions
too are largely discretionary and decision-making on a
local level remains vitally important. Cost effectiveness
analyses are a key component of that NICE appraisal
process of new treatments, and NICE has a threshold
range of £20,000 - £30,000 per additional QALY. If a
treatment has an ICER above this threshold, then it is
unlikely to get a positive recommendation. The NICE
threshold may be adopted by local decision makers, in
the absence of a local threshold although in practice
there appears to be wide variation in local spending de-
cisions [14]. Due to the chronic nature of longer-term
depression, an estimate of lifetime costs and benefits is
required [15]. Mathematical modelling methods are used
to extrapolate short-term clinical trial evidence, as well
as incorporating longer term observational data, to esti-
mate lifetime costs and QALYs [16].
Mathematical models have frequently been applied to
services of care for patients with depression, including
NICE guidance [17] and guidelines [3,18,19]. Some have
considered screening for depression [20] and others for
recurrence prevention [10,11], However these models
are concerned with treatments at one point in a patient’s
pathway. Models identified in published systematic re-
views were often only short-term, and were not flexible,
so do not allow a consideration of the different possibi-
lities at various points in a person’s pathway [21-23].
Tappenden et al. [24] have recently developed a ‘Whole
Disease Model’ for colorectal cancer which provides a
consistent platform through which to evaluate the cost-
effectiveness of potential policy changes within the UK
colorectal cancer service. This form of modelling moves
away from the notion of considering the optimal policy
at an isolated point in the broader care pathway, to mod-
elling the pathway itself and the range of decisions
therein. In taking this broader perspective, Whole Dis-
ease Modelling can be used to address a much wider
range of questions considering the configuration of
health services with the intention of improving overall
health outcomes across the system.
Tappenden et al. [24] have developed a methodological
framework for Whole Disease Modelling, and this ana-
lysis draws upon this framework, to enable the evalu-
ation of multiple changes to the care pathway for
depression treatment in the NHS.
Methods
The aim of this study was to demonstrate the use of
whole system cost effectiveness modelling within a health
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an NHS Foundation Trust providing mental health ser-
vices and 109 primary health care centres serving a
population of 555,500. Its Foundation Trust status means
it has managerial and financial independence from the
Department of Health and local NHS health authorities
with regards to how services are provided. Ethical ap-
proval was granted by the National Research Ethics Ser-
vice (NRES) for the study (REC 10/H1310/51). Only
anonymised routine NHS data were used in the analysis
and as such participant consent was not required.
Conceptual model
The first stage of the process was to develop two concep-
tual models, through interviews with local mental health
service experts (managers, service users, clinicians and ac-
ademics), as well as from the relevant research literature.
First, a disease-level conceptual model was developed
(Figure 1). Longer-term depression is characterised by a
person relapsing from remission or recovery into a depres-
sive episode (recurrent depression), or by a treatment fail-
ing to see an improvement in a person’s condition
(treatment-resistant/persistent depression). Whether a per-
son is in response, remission or recovery is dependent on
how long their normal mood has lasted since a depressive
episode.
Secondly, a service-level conceptual model was devel-
oped to describe the delivery of psychological therapy ser-
vices for people with longer-term depression in Sheffield,
England. At this stage, and at intervals throughout the
study, an expert workshop was convened consisting of
mental health service commissioners, primary and sec-
ondary care clinical staff, service managers, academic
specialists and service users. The function of the expert
workshop was to advise on the conceptual model and to
generate consensus on priorities for evidence-based
innovations.Persistent Depression
Normal Moo
Depressive Episode Relapse
Respons
Recurren
Figure 1 Disease level conceptual model.In general, Sheffield has adopted the stepped care
model (SCM) as recommended in the 2009 NICE Cli-
nical Guideline for Depression [3]. The SCM is a struc-
tured pathway of care for people with depression,
directing people to the most appropriate and least costly
interventions. The SCM spans primary, secondary and
tertiary care services in Sheffield, with access points
across medical, third sector and public sector services.
Improving Access to Psychological Therapies (IAPT)
services with low and high intensity PT are provided in
primary care, along with medical therapies provided by
general practitioners before IAPT is initiated. Commu-
nity Mental Health Teams (CMHTs) in secondary care
provide more complex and comprehensive medical treat-
ment and PT for people with longer-term depression.
People can also step up to tertiary care and the Specialist
Psychotherapy Services (SPS) which includes a team fo-
cussed on treatment of severe and complex depression.
Mathematical model
The conceptual model was agreed by the expert work-
shop as the basis for the fundamental assumptions of
the mathematical models’ structure. The mathematical
model reflects the relapsing/remitting characteristic of
longer-term depression by simulating these two possible
health states as evidenced in the disease level conceptual
model. The mathematic model assigns probabilities to a
patient moving from one point to another, simulating
patient pathways through the service system. These
probabilities are calculated using evidence from a range
of sources, which allows the model to estimate the costs
and health benefits of the current care pathway.
The estimates of costs and health benefits provide a
baseline estimate of efficiency within the service. The
model was then used to estimate the impact of changes
to the service i.e. does a change to the service affect
health benefits and costs? The model was therefore usedd
RecoveryRemissione
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saving, or cost-effective.
A discrete event simulation model was developed in
Simul8©. This methodology estimates the costs and QALYs
for unique simulated people, and after running 1,000 simu-
lated people the average cost and QALY per person are cal-
culated. This approach is different from a cohort/Markov
model methodology, because individual patients with
unique characteristics are simulated, rather than an average
cohort. This overcomes the limitations of Markov models
and allows a greater degree of complexity to be incorpo-
rated [25]. Both costs and QALYs are discounted at 3.5%
each year, in line with current guidance to account for time
preferences [15]. The simulation of the patient pathway is
shown in Figure 2. The simulation model has work centres
for each event. A work centre contains logic to determine
movements to future work centres (i.e. a movement from a
GP consultation to a GP treatment decision). Work centres
also update the costs and health benefits for a patient as
they are simulated. In Box 1 (Condition) of the simulation
model, patients are simulated to be in a normal state or a
depressive episode. If they have a depressive episode, then
they can present to NHS services via Box 2. The patient
can then step through primary care treatment, IAPT ther-
apies (Box 3), CMHTs (Box 4) and tertiary SPS (Box 5).
Each treatment step begins with an initial assessment to de-
termine if treatment is appropriate. If so, the patient is
treatment, and their subsequent route through the model is
then determined based on their response to treatment.
When a depressive episode ends, either naturally or due to
successful treatment, they return to the normal state work
centre in Box 1. The simulated patients are modelled until
they die and proceed to Box 6.Figure 2 Simulation model.Comparators
The IQuESTS expert workshop generated consensus on
evidence-based innovations for service improvement.
From many suggested topics, twelve were selected for
discussion at a workshop and eight were included in a
Delphi exercise. From the workshop and Delphi, three
were selected for evaluation in the model by the research
team via a discussion based on their ease of modelling.
One of the workshops was also used to validate the con-
ceptual and mathematical models.
Self-referral back to therapy after discharge
In current services, after discharge from the psycho-
logical therapy service, a new episode of depression
would require re-referral back to the team via the GP, ne-
cessitating a further wait. In this service change, self-
referral can occur if the next depressive episode happens
within 6 months of a response to PT. It costs an extra
session and the person is fast-tracked back into a course
of PT. It is assumed that the details are provided to the
person on a contact card on discharge from the service.
At the workshop, experts commented that this is some-
times informally provided. The main anticipated benefit
is the reduction in time to re-enter PT for people with re-
lapsing depression.
Better management and prevention of drop-out from
psychological therapy
Almost 50% of people will drop out of PT [26,27]; how-
ever interventions to address this significant problem
have not been widely developed. There is some evidence
to suggest that psychotherapy dropouts might be
minimised if differences between therapists’ and patients’
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edged and recognised as legitimate targets for interven-
tion. This supports an additional therapist session
specifically to address these issues and to develop collab-
orative strategies with the aim to reduce dropout [28-30].
The model simulates this service change by a 20% reduc-
tion in the probability of drop-out in primary, secondary
and tertiary PT. This costs one therapist session, for the
development of management and coping strategies. The
modelled assumptions of costs and effectiveness were
considered and agreed by the expert workshop.
Widening access to non-therapy services
Service users reported benefit from accessing a range of
non-therapy services that fall outside traditional PT and
medical services, including social groups, exercise, medi-
tation, complementary, physical and creative therapies.
Widening access to these through NHS signposting may
enhance self-management and see more suitable and
beneficial care being provided. The model simulates this
service change via a 10% reduction in drop-out, and a
10% increase in response to treatment. The service costs
one therapist session. It is assumed that the NHS is only
signposting a patient to these services, and not funding a
course of non-therapy support. The modelled assump-
tions of costs and effectiveness were considered and
agreed by the expert workshop.
Model population
The population is defined as people using longer-term
depression services. This has been more explicitly de-
fined as people with a diagnosis of recurrent or chronic
depression, or more than two separate depressive epi-
sodes (ICD codes F32, F33, F34, F38.1 and F41.2). Pa-
tients identified could have comorbidities; however
depression was the primary diagnosis for the routine
NHS data. Each patient is assigned a number of charac-
teristics which determine their route through the model.
These characteristics included their current disease sta-
tus (depressive episode or normal state), age, health re-
lated quality of life, and previous history in the model
(number of previous depressive episodes, and response/
non-response to previous treatments).
The model estimates a ‘natural history’ for each simu-
lated person. The time spent either depressed or well is
modelled without the impact of any health services or in-
terventions. This represents the profile for a person who
does not engage with services, or the subsequent profile
for someone who drops-out of the system. Effective treat-
ments impact on the natural history of the condition by
reducing the severity of the episode, shortening the epi-
sode, or increasing the time until a relapse. A treatment
can be effective in multiple ways, and increasing the time
until relapse has long-term health benefits. A mortalityimpact of longer-term depression has not been modelled,
with life expectancies taken from published life tables [31].
Data
All data parameters and sources are provided in Table 1.
Evidence to inform the model was obtained from a range
of sources. Resource and time constraints prevented a
full systematic review of the literature, and therefore a
non-systematic rapid review surrounding the diagnosis,
treatment and follow-up of longer-term depression was
undertaken. We also searched NICE guidance regarding
depression, and the NICE Clinical Guideline for depres-
sion was a major source of systematically reviewed evi-
dence [3]. NHS Reference Costs were used to identify
costs of services, and routinely collected data from the
local mental health trust were analysed for this model.
Only NHS costs were incorporated, with the analysis
therefore taking a funder perspective. Where data were
not available, clinical expert opinions were used to pro-
vide informed assumptions.
Analysis
The model simulates 1,000 people, to provide an estimate
of the mean cost and QALYs per person. Probabilistic Sen-
sitivity Analysis (PSA) was undertaken to quantify the un-
certainty in the parameter data, and this was performed by
running 500 additional simulations drawing from assigned
distributions for each parameter input. In particular,
Weibull distributions were applied for the epidemiological
parameters, beta distributions for probabilities and util-
ities, and uniform distributions for the NHS reference
costs. Analyses were performed to ensure that these were
an appropriate number of simulations. Validation of the
model was performed by testing the model code and
checking results and this was performed by a second ana-
lyst. Error checking was undertaken, and the face validity
of the model was constantly tested by the project team
and steering group. Scenario analyses were performed, by
changing model assumptions to test the sensitivity of the
cost-effectiveness results. A factorial design analysis was
undertaken to evaluate the impact of undertaking multiple
service changes at the same time.
Results
Service impact
Table 2 provides more detailed results regarding the im-
pact of the service changes on the longer-term depression
health service. The table also shows that on average, a per-
son experiences nine depressive episodes. The results for
visits to primary, secondary and tertiary are for complete
courses of care, and so on average people are much more
likely to receive care in primary services (2.9 courses of
treatment) rather than secondary (0.1 courses) or tertiary
(0.05 courses). The table shows that there is a small
Table 1 Model parameters
Parameter Value Evidence source and type
Epidemiological
Length of untreated episode of recurrent depression 3rd episode: 0.55 years. [32] 10 year observational study
4th episode: 0.60 years
5th episode +: 0.43 years
Probability of no future recurrence of depression 2 prior episodes: 0.3. [33]
3+ prior episodes: 0.1
Time to relapse 0.93 years [34] 15 year observational study
Clinical presentation
Probability of presenting to services during depressive episode 0.40 [35] Consensus document
Probability of no relapse after cognitive behavioural therapy
(CBT) response
0.75 [36] Randomised controlled trial
Primary care
Probability of medical therapy (even if stepping up) Assumed 100% Clinical expert assumption
Probability of response after 8 weeks of mirtazapine
anti-depressant therapy
0.63 [3,37] NICE Clinical Guideline
Probability of IAPT referral Assumed 100% Clinical expert assumption
IAPT
Probability of low intensity IAPT 0.68 SHSC data
Probability of high intensity IAPT 0.32
Probability of effective low intensity IAPT
(> 10 point improvement in PHQ9)
0.24
Probability of effective high intensity IAPT
(> 10 point improvement in PHQ9)
0.54
Probability of completing low intensity IAPT 0.35
Probability of completing high intensity IAPT 0.35
Number of low intensity IAPT sessions 3 + 1 assessment
Number of high intensity IAPT sessions 7 + 1 assessment
Length of course of low intensity IAPT 0.42 years
Length of course of high intensity IAPT 0.71 years
Community Mental Health Teams
Time from referral to assessment 0.08 years (4 weeks) Clinical expert opinion
Probability of accepted at assessment 0.8
Treatment effectiveness CMHT treatment effectiveness assumed
equal to IAPT
Specialist Psychotherapy Services
Probability of being accepted at SPS assessment 0.71 SHSC data
Treatment effectiveness SPS treatment effectiveness assumed equal
to IAPT
Clinical expert opinion
Costs
GP £38 2009 NHS Unit Costs
IAPT Therapist (per session) £88 2010 NHS Reference Cost
CMHT Assessment £212
CMHT Therapist (per session) £135
SPS Assessment £139
SPS Therapist (per session) £139
Mirtazapine treatment. 30 mg daily,
8 week course which if effective is maintained
£4.08 per course BNF 61
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Table 1 Model parameters (Continued)
Health Utilities
Untreated severe depression 0.30 [3,38] NICE Clinical Guideline/Cohort
analysis
In health service, severe depression 0.58
Minimal depression/normal health 0.85
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will experience on average.
The self-referral service change, as expected, predicts a
reduction in primary care visits, with people instead being
fast tracked back to secondary and tertiary services. The
number of PT courses being completed increases. This is
due to people bypassing antidepressant treatment offered
in primary care, and moving straight back to PT. The total
effect is an increase in the costs attributed to each level of
the service. The increase in primary care costs is mostly
driven by the increase in high intensity IAPT. This service
change bypasses GP treatment and antidepressant therap-
ies, which are modelled as effective in this patient popula-
tion, and have lower drop-out rates than PTs.
The reduce drop-out service change has the expected ef-
fect of increasing visits across secondary and tertiary ser-
vices. It also results in a greater number of psychological
therapy courses being completed. The total effect is an in-
crease in the cost of providing services across all levels.
The increase in access to non-therapy services sees neg-
ligible change in service use, which results in only a slight
increase in total costs when compared to the basecase.
This may be due to the way in which non-therapy services
have been modelled, and this will be discussed further in
the Discussion section. This is the only service change
which results in a cost saving for any individual part of the
pathway (secondary and tertiary care), due to patients hav-
ing less time with untreated depression, and so they do
not step up in the system.
Cost effectiveness
Table 3 provides estimates of the costs and QALYs gene-
rated by the baseline configuration, and the three service
changes. The results presented are from the probabilistic
sensitivity analysis (PSA), and are discounted, and the in-
cremental analysis for each service change is compared to
the basecase model.Table 2 Service impact results
Model Episodes System results
Primary visits Secondary visits Ter
Baseline 9.283 2.994 0.148 0.04
Self-referral 9.196 2.486 0.160 0.0
Reduce drop-out 8.754 2.788 0.192 0.0
Non-therapy 8.823 2.793 0.118 0.02
Values in bold show an increase compared to baseline.All three service changes result in additional QALYs,
when compared to current care. These additional QALYs
come at an increased cost for all three changes. The self-
referral change is both more effective (+0.011 QALYs) and
more costly (+£127), which results in an ICER of £11,378
per additional QALY, when compared to current care. The
reduce drop-out change generates the greatest additional
QALYs (+0.087), but also at an additional cost (+£194),
which results in an ICER of £2,227 per additional QALY,
when compared to current care. The non-therapy change
is more effective (+0.074) and more costly (+£16), which
results in an ICER of £223 per additional QALY, when
compared to current care.
Figure 3 presents the PSA results in the form of a cost
effectiveness acceptability curve (CEAC), which indicates
the probability that a service change is cost-effective for
a range of ICER thresholds when compared to current
practice. The CEAC shows that both the reducing drop-
out and non-therapy service changes are likely to be
cost-effective at a £20,000 per additional QALY thresh-
old compared to current practice (probability > 0.98). At
this threshold level, the self-referral change has a prob-
ability of being cost-effective of 0.57.
The CEACs highlight that there is uncertainty in the
model parameters, which results in uncertainty as to
whether a service change will be cost-effective. The 500
PSA simulations provided estimates of negative incremen-
tal QALYs for all three service changes. Only a small num-
ber of simulations for the non-therapy service change
resulted in negative incremental costs (i.e. saved money).
This suggests that all three options are likely to require
additional NHS resources for implementation.
Scenario analysis
Scenario analysis was undertaken on the self-referral ser-
vice change, by varying the time for which self-referral is
an option. The basecase time limit for self-referral isPT
courses
Costs (undiscounted), £
tiary visits Primary Secondary Tertiary Total
8 1.398 £666 £171 £50 £886
62 1.493 £759 £208 £78 £1,046
77 1.423 £760 £244 £95 £1,099
6 1.288 £716 £143 £31 £891
Table 3 Cost-effectiveness results
Model/service
change
QALYs Cost (£) Cost-effectiveness (compared to current care)
Incremental QALYs Incremental costs ICER
Current care 15.023 £699.56 - - -
Self-referral 15.034 £827.02 0.011 £127.46 £11,378
Reduce drop-out 15.110 £893.87 0.087 £194.30 £2,227
Non-therapy 15.096 £716.03 0.074 £16.47 £223
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limits. Extending the time limit to 12 months marginally
worsened the incremental cost-effectiveness ratio of the
self-referral service change (ICER £3,968 per QALY
compared to current care).
For the reduce drop-out service change, scenario ana-
lyses were undertaken by varying the percentage reduc-
tion in drop-out assumed by the new service. The
results were in general insensitive to varying the reduc-
tion in drop-out between 5% (£5,835 per QALY) and
25% (£2,175 per QALY). The results for the non-therapy
service change were also relatively insensitive to changes
in the drop-out rate and treatment efficacy.
Factorial analysis
A factorial design was undertaken with all possible combi-
nations of the three service changes being ‘on’ or ‘off ’. This
therefore examines if there are any interactions between
the services and if a combination of service changes offer
greater value for money.
Table 4 presents a fully incremental analysis of the cost-
effectiveness results from the factorial design analysis. As
expected, the basecase configuration is least effective
(14.912 QALYs). Factor combinations 3, 6 and 5 are domi-
nated by (are less effective and more costly than) factor
combination 7. The ICER for factor 7 compared to factor
4 (the next less effective and non-dominated comparator)
is £5,533 per additional QALY.0
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Figure 3 Cost effectiveness acceptability curve.The factor combination 2 is dominated by factor com-
bination 4. Compared to the basecase, factor combin-
ation 4 has an ICER of £1,335 per additional QALY.
Factor combination 8 has all three service changes ac-
tive, and is the most effective factor combination. Com-
pared to factor combination 7 it has an ICER of £24,586
per additional QALY. It is important to note that factor
combination 8 is not the most costly option, which in-
stead is factor combination 5. This is interesting because
each individual service change has a cost impact for the
NHS. Having a total cost lower than an option with only
two service changes suggests that important interactions
in the service are occurring when multiple changes are
made.
Discussion
The results suggest that all three proposed service
changes would provide health benefits, accounted for by
increasing the use and completion of psychotherapy ser-
vices. As well as the immediate benefit of reducing the
length of a depressive episode, the service changes have
the long-term benefit of reducing the probability of fu-
ture episodes of depression. These additional benefits
however come at an increased cost for the NHS, due to
increased utilisation of services and psychological ther-
apies. The sensitivity analyses (probabilistic, and scenario
analysis) undertaken suggest that these results are robust
to the model assumptions. The factorial design provides60000 80000 100000
cceptable ICER
cceptability Curve
Self-referral Non-therapy
Table 4 Factorial design results
Design Self-
referral
Drop-out
reduction
Widening
non-therapy
QALYs Costs Incremental analysis
ICER Comparatora
1 - - - 14.912 £832 -
2 - + - 14.935 £1,512 Dominated Compared to 4
4 + - + 14.956 £891 £1,335 Compared to 1
3 + - - 14.964 £1,166 Dominated Compared to 7
6 - - + 14.986 £1,568 Dominated Compared to 7
5 + + - 15.002 £2,065 Dominated Compared to 7
7 - + + 15.019 £1,150 £5,533 Compared to 4
8 + + + 15.042 £1,993 £24,586 Compared to 7
Results ordered from smallest to largest QALYs - = factor not active + = factor active.
a Comparison against the next less-effective non-dominated option.
Tosh et al. BMC Health Services Research 2013, 13:150 Page 9 of 11
http://www.biomedcentral.com/1472-6963/13/150evidence for policy makers when considering multiple po-
tential changes, but also highlights that unexpected inter-
actions may occur and should be carefully considered.
Due to the local nature of the research and decision-
maker environment, there is not a defined cost-effectiveness
threshold based on local spending and outcomes. This
means that interpretation of the cost-effectiveness results
cannot be undertaken by this research team, but will need
consideration by NHS commissioners and providers. Whilst
some national guidance from NICE is mandatory, NICE has
only considered a sub-set of possible interventions and
treatments and so local policy-making requires evidence to
inform it. The use of UK specific data and taking a UK per-
spective does limit the results of this analysis to a UK con-
text; however we anticipate that the methodologies and
concepts will be transferable to other countries.
The results of the analysis highlight the flexibility and
appropriateness of the Whole Disease Modelling frame-
work when looking to evaluate service changes which
will have a wide and long-term impact. Each of the three
service changes was evaluated in terms of their impact
across the NHS, and for a patient’s lifetime.
The quantified model also provides useful service per-
formance metrics, such as flows of people through different
parts of the services, and changes can be evaluated in terms
of their impact on specific resources. This is important be-
cause the local NHS is currently going through a period of
change, and in general budgets are being restricted.
One important result is that the model suggests only
low numbers of people with longer-term depression ‘step
up’ to secondary (CMHT) and tertiary (SPS) services. This
is because only a small proportion will present, and also
because by the time they reach these higher steps, the de-
pressive episode may have passed without a healthcare
intervention. In particular, the self-referral service change
highlights that if people can quickly receive appropriate
therapy then there are likely to be significant health bene-
fits both immediately, and in the longer term.As with any health economics modelling, there are
limitations of the analysis which should be noted. First,
the analysis of the local NHS dataset has only been to
identify broad flows of patients in the service, and covar-
iates such as ethnicity and severity of depression have
not been incorporated into the analysis. Secondly, health
economic modelling allows evidence from different
sources to be synthesised so that an estimate of the long
term costs and benefits of new interventions can be
found. As such, the model is limited by the quality of
evidence that is available, and by the assumptions used
when evidence is missing. The basecase model results
suggest that patients experience on average nine depres-
sive episodes in their lifetime. This is derived from longi-
tudinal studies which estimate a time to relapse after a
particular number of episodes, however evidence regard-
ing relapse beyond five episodes was not identified, and
so the model simulates a potentially inaccurate number
of episodes. Experts suggest that this number may be
too high, however it should be noted that there is still a
low probability of patients presenting, and so these epi-
sodes may go undetected.
There is a significant evidence gap regarding the effect-
iveness of therapies at the higher steps (CMHTs and SPS).
For this attempt at modelling the service, the effectiveness
of SPS psychological therapy has been assumed no better
than CMHT input. Because the IQuESTS project includes
a specialist depression research clinic to pilot these service
improvements, many of these assumptions can be tested
and this will benefit the model in terms of collecting long
term data regarding patients’ experiences with depression,
and the impact of specific service improvements. This
data will be used in an updated version of the model once
the pilot study has been completed.
Mortality and serious adverse events have not been in-
corporated into the model. People who suffer a severe
depressive episode have a significantly increased suicide
risk, as well as increased risk of self-harm resulting in
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depression will never access health services. Better ac-
cess to services for these people will enable effective care
and services to be provided, leading to improved health
outcomes.
Because the service changes that have been evaluated
are novel and un-evidenced, assumptions have been re-
quired to incorporate these changes into the model.
Relatively simplistic assumptions have been required,
such as the cost implications of the changes, and how
they may impact on the flows of people through the sys-
tem. The next step of the IQuESTS project is to explore
fully how these service changes will be implemented in a
pilot study. These results will inform the further devel-
opment of the service changes, but may also allow an
opportunity for refining the assumptions in the model
and improving the accuracy of the results.
The Whole Disease Model framework provides a use-
ful set of stages for a research project of this type. Be-
cause a change to a system can impact on other services,
it is important to have a wide boundary and ensure that
all possible costs and benefits are incorporated into the
analysis. This aids decision-makers and commissioners,
who are often challenged when provided with economic
analyses which have a very specific boundary (i.e. a pair-
wise evaluation of treatments which does not capture
the full care pathway). Also, the Whole Disease Model-
ling framework allows multiple evaluations of service
changes to be undertaken. At this stage, three different
service changes have been evaluated, however more can
be added relatively easily, which means the Whole Dis-
ease Modelling framework allows efficient use of one
(potentially more complex) model, rather than requiring
several models.Conclusions
This study has used the novel Whole Disease Modelling
framework to allow a single mathematical model to
evaluate several changes to the Sheffield mental health
NHS service for people with longer-term depression.
The output of this research suggests that reducing drop
out, widening access to non-therapy services, and
allowing self-referral may have health benefits for people
with longer-term depression. However these additional
health benefits may be at an increased cost for the NHS.
With research currently being undertaken to examine
these changes in clinical practice, we have used model-
ling methods to translate evidence into service change
and health improvements for patients. The research has
also shown that the Whole Disease Modelling frame-
work is a robust and efficient method for modelling
multiple service changes using a coherent and validated
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